Investigators have determined that in children receiving gadolinium as a contrast agent to enhance MRI examinations, signal changes attributed solely to deposition of this material in the brain are not dependent on the amount of gadolinium administered but rather these changes are seen in association with other factors such as the presence of brain tumors and treatment using brain irradiation.